APTT Ellagic Acid Solution: Protocol & Lab Guide

APTT ellagic acid solution is a standardized contact-phase activator reagent used to initiate the intrinsic coagulation cascade in activated partial thromboplastin time (APTT) assays, enabling precise evaluation of clotting factor activity and anticoagulant therapy monitoring.

Product SKU

A1356028B

Function

Contact-phase activator for APTT coagulation assays

Target Pathway

Intrinsic (contact activation) coagulation pathway

Primary Application

Activated partial thromboplastin time (APTT) measurement

Specimen Type

Citrated platelet-poor plasma (PPP)

Storage

Store as directed on product label; protect from light

Principle and Background

The activated partial thromboplastin time (APTT) is a globally used coagulation test that evaluates the intrinsic and common coagulation pathways. It is routinely employed to monitor unfractionated heparin therapy, screen for factor deficiencies (Factors VIII, IX, XI, XII, prekallikrein, and high-molecular-weight kininogen), and detect lupus anticoagulants.

Ellagic acid, a polyphenolic compound, functions as a contact activator by binding to Factor XII (Hageman factor) and triggering the contact activation pathway. When ellagic acid is added to platelet-poor plasma, it activates Factor XII, which sequentially activates Factor XI, Factor IX, and ultimately Factor X, leading to the generation of thrombin and fibrin clot formation. Compared to older activators such as kaolin or celite, ellagic acid provides a more consistent and reproducible surface for contact activation, reducing inter-assay variability.

The APTT ellagic acid solution (SKU: A1356028B) from Aladdin Scientific is formulated to deliver reliable contact-phase activation suitable for manual, semi-automated, and automated coagulation analyzer workflows.

Materials and Equipment Required

• APTT ellagic acid solution (Aladdin Scientific, SKU: A1356028B)
• Citrated platelet-poor plasma (PPP): collected in 3.2% sodium citrate vacutainer tubes, centrifuged at 2,000–2,500 × g for 15 minutes at room temperature
• 0.025 M calcium chloride (CaCl₂) solution, pre-warmed to 37 °C
• Coagulation analyzer or manual tilt-tube setup capable of 37 °C incubation
• Micropipettes and calibrated tips (100 µL and 200 µL range)
• Polypropylene or glass cuvettes compatible with your analyzer or tilt-tube method
• Timer (if performing manual method)
• Personal protective equipment (PPE): lab coat, nitrile gloves, eye protection

Note: All reagents and plasma samples should be equilibrated to 37 °C in a water bath or instrument incubation block before use. Avoid repeated freeze-thaw cycles of plasma specimens.

Step-by-Step APTT Protocol

Step 1 – Reagent Preparation

Remove the APTT ellagic acid solution (A1356028B) from storage and allow it to reach the temperature specified on the product label. Gently mix by inversion; do not vortex. Pre-warm the reagent and CaCl₂ solution to 37 °C for at least 3–5 minutes before use.

Step 2 – Plasma Preparation

Prepare citrated platelet-poor plasma by centrifuging whole blood collected in 3.2% sodium citrate tubes at 2,000–2,500 × g for 15 minutes. Transfer the supernatant carefully, avoiding the buffy coat. Use plasma within 4 hours of collection when stored at room temperature, or freeze at −70 °C for longer storage.

Step 3 – Incubation with Contact Activator

Pipette 100 µL of patient or control plasma into a pre-warmed cuvette. Add 100 µL of APTT ellagic acid solution. Mix gently and incubate at 37 °C for 3–5 minutes to allow complete contact activation. The exact incubation time should be validated against your specific instrument or method.

Step 4 – Clot Initiation

Add 100 µL of pre-warmed 0.025 M CaCl₂ solution to the plasma–activator mixture. Start the timer (or initiate instrument measurement) immediately upon CaCl₂ addition. Record the time to clot formation (fibrin end-point detection).

Step 5 – Result Recording

Record the APTT clotting time in seconds. Run normal and abnormal quality-control (QC) plasma samples with each batch. Compare results to your laboratory-established reference interval. A typical reference range for APTT in healthy adults is approximately 25–35 seconds, but laboratories must establish their own reference intervals.

Important: Always follow your laboratory's standard operating procedure (SOP) and the instrument manufacturer's guidelines. This protocol provides general guidance only.

Troubleshooting and Quality Control

Problem	Possible Cause	Recommended Action
Prolonged APTT in all samples	Reagent degradation; incorrect CaCl₂ concentration; inadequate incubation temperature	Check reagent expiry and storage conditions; verify CaCl₂ molarity; confirm instrument temperature at 37 °C
Shortened APTT	Plasma not properly anticoagulated; incorrect plasma:anticoagulant ratio; lipemic or hemolyzed sample	Verify blood collection tube fill volume; reject grossly hemolyzed or lipemic samples
High inter-assay variability	Inconsistent incubation time; pipetting error; reagent not mixed before use	Standardize incubation timing; calibrate pipettes regularly; mix reagent gently before each use
QC values out of range	Reagent lot change; instrument malfunction	Retest with fresh QC material; perform instrument maintenance; contact technical support

Run at least two levels of QC (normal and abnormal) at the beginning of each shift or analytical run. Document all QC results and corrective actions according to your laboratory's quality management system.

Safety, Storage, and Disposal

Safety: Handle APTT ellagic acid solution with standard laboratory precautions. Wear appropriate PPE including lab coat, nitrile gloves, and eye protection. The reagent may contain human or animal plasma components; treat as potentially biohazardous. Consult the product Safety Data Sheet (SDS) for full hazard information before use.

Storage: Store according to the conditions stated on the product label and SDS. Protect from light. Avoid repeated freeze-thaw cycles. Do not use reagent beyond the stated expiry date. Record lot number and expiry date upon receipt.

Disposal: Dispose of all biological specimens, used reagents, and contaminated materials in accordance with local, national, and institutional regulations for biohazardous waste. Do not pour reagents down the drain without verifying compliance with applicable waste disposal regulations.

Frequently asked questions

What is the role of ellagic acid in the APTT assay?

Ellagic acid acts as a contact activator that binds Factor XII (Hageman factor) to initiate the intrinsic coagulation pathway. It provides a consistent negatively charged surface that triggers contact activation, leading to sequential activation of Factors XI and IX and ultimately clot formation. Its use results in more reproducible APTT results compared to particulate activators such as kaolin.

How should I store the APTT ellagic acid solution to ensure stability?

Store the reagent strictly according to the conditions specified on the product label and Safety Data Sheet. Protect from light and avoid repeated freeze-thaw cycles. Always note the lot number and expiry date upon receipt, and do not use the reagent after the stated expiry date. Consult Aladdin Scientific's technical support if you have specific storage questions.

Why must plasma samples be platelet-poor for APTT testing?

Platelets contain phospholipids and coagulation factors that can independently contribute to clot formation, potentially shortening the APTT and causing inaccurate results. Platelet-poor plasma (PPP), typically achieved by centrifugation at 2,000–2,500 × g for 15 minutes, ensures that the APTT reagent's own phospholipid component drives the reaction reproducibly, giving standardized results.

Can this reagent be used on automated coagulation analyzers?

The APTT ellagic acid solution (A1356028B) is designed to be compatible with manual, semi-automated, and automated coagulation analyzer workflows. However, users should validate reagent performance on their specific instrument according to local laboratory accreditation requirements and the instrument manufacturer's recommendations before routine clinical use.

What controls should I run alongside patient samples?

Always include at least two levels of quality control plasma—a normal control and an abnormal (elevated APTT) control—with each analytical run. QC results must fall within established acceptance limits before patient results are reported. Additionally, certified reference plasma or manufacturer-supplied controls may be used for method validation and calibration verification.

References

1. Langdell RD, Wagner RH, Brinkhous KM. Effect of antihemophilic factor on one-stage clotting tests: a presumptive test for hemophilia and a simple one-stage partial thromboplastin time test. J Lab Clin Med. 1953;41(4):637–647.
2. Proctor RR, Rapaport SI. The partial thromboplastin time with kaolin: a simple screening test for first stage plasma clotting factor deficiencies. Am J Clin Pathol. 1961;36:212–219.
3. Clinical and Laboratory Standards Institute (CLSI). One-Stage Prothrombin Time (PT) Test and Activated Partial Thromboplastin Time (APTT) Test. CLSI Document H47-A2. Wayne, PA: CLSI; 2008.
4. Triplett DA. Use of the dilute Russell viper venom time (dRVVT): its importance and pitfalls. J Autoimmun. 2000;15(2):173–178.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.